218 results on '"Pisaneschi, Federica"'
Search Results
2. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine
3. Imaging of innate immunity activation in vivo with a redox-tuned PET reporter
4. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging
5. Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology
6. Hypoxia-activated prodrug and anti-angiogenic therapy cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration
7. Combining Positron Emission Tomography and Hyperpolarized Magnetic Resonance to Interrogate Prostate Cancer Metabolism
8. Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Radioligand Therapy Applications
9. cGMP synthesis of 4-[18F]fluoro-1-naphthol, a novel PET tracer for imaging activation of innate immunity
10. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
11. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib
12. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging
13. Abstract 3097: Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate enolase inhibitor for the treatment of ENO1-deleted cancers
14. Abstract 5036: Single dose treatment with a novel Yttrium-90-labeled high affinity anti-B7-H3 antibody selective for the 4Ig-B7-H3 isoform provides long term survivors for established radioresistant colorectal carcinoma
15. O-71 - cGMP synthesis of 4-[18F]fluoro-1-naphthol, a novel PET tracer for imaging activation of innate immunity
16. O-36 - Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Radioligand Therapy Applications
17. O-26 - Combining Positron Emission Tomography and Hyperpolarized Magnetic Resonance to Interrogate Prostate Cancer Metabolism
18. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
19. Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers
20. Apoptosis Detection in Retinal Ganglion Cells Using Quantitative Changes in Multichannel Fluorescence Colocalization
21. Preclinical evaluation of a CXCR4-specific 68Ga-labelled TN14003 derivative for cancer PET imaging
22. Abstract 2463: 18F-Talazoparib: A novel potential PET imaging agent of PARP
23. Abstract 2488: PET imaging of innate immunity activation In Vivo with redox-tuned 4-[18F]fluoro-1-naphthol
24. Radiometal-Based PET/MRI Contrast Agents for Sensing Tumor Extracellular pH
25. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging
26. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine.
27. Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation
28. Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology
29. ENBPI ligand for 68Ga: synthesis, radiolabeling optimization, and pilot myocardial perfusion imaging with ECG-gated PET
30. [18F]Talazoparib: a novel potential PET imaging agent of PARP
31. Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s- cis peptide bond as integrin α vβ 3 and α vβ 5 ligands
32. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
33. A novel radio-pharmaceutical to image activation of the innate immune system in vivo
34. Evaluation of the Biodistribution of Serinolamide-Derivatized C60 Fullerene
35. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo
36. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma
37. New developments in the synthesis of pyrrolizidinone-based dipeptide isosteres
38. Development of a Potential Gallium-68-Labelled Radiotracer Based on DOTA-Curcumin for Colon-Rectal Carcinoma: From Synthesis to In Vivo Studies
39. Multiwalled carbon nanotubes for combination therapy: a biodistribution and efficacy pilot study
40. SP-041 - ENBPI ligand for 68Ga: synthesis, radiolabeling optimization, and pilot myocardial perfusion imaging with ECG-gated PET
41. O-10 - [18F]Talazoparib: a novel potential PET imaging agent of PARP
42. Diastereoselective cycloaddition of alkylidenecyclopropane nitrones from palladium(0)-catalyzed nucleophilic substitution of asymmetric 1-alkenylcyclopropyl esters by amino acids
43. Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT
44. Abstract LB-367: [18F]FAZA PET imaging reveals precise pharmacodynamics in vivo of the novel chemotherapeutic IACS-010759
45. Eradication of ENO1-deleted Glioblastoma through Collateral Lethality
46. Combined therapies with nanostructured carbon materials: there is room still available at the bottom
47. Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer
48. A new bicyclic dipeptide isostere with pyrrolizidinone skeleton
49. Automated, Resin-Based Method to Enhance the Specific Activity of Fluorine-18 Clicked PET Radiotracers
50. SF2312 is a natural phosphonate inhibitor of enolase
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.